Advanced Oncotherapy (AVO) today announced it has signed a non-binding agreement for additional financing from a third-party investor. The company said the deal was expected to provide funding of up to c.$80m to meet its cashflow requirements through to certification of its next generation proton beam therapy system LIGHT. The transaction is subject to agreement on…
Membership Required
You must be a HM Subscriber to view this content.
Already have an account? Sign In
©2025 All rights reserved LaingBuisson 
 today announced it has signed a non-binding agreement for additional financing from a third-party investor.){kind=link}